Search

Displaying results 821 - 830 of 4236 in total
  1. Drug

    Vorapaxar

    go.drugbank.com/drugs/DB09030
    Approved

    Vorapaxar is a tricyclic himbacine-derived selective inhibitor of protease activated receptor (PAR-1) indicated for reducing the incidence of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or wi...

  2. Drug

    Simethicone

    go.drugbank.com/drugs/DB09512
    ApprovedInvestigational

    [A228308] It has a favourable safety profile as it is not systemically absorbed.[A228308] Simethicone has been in use since the 1940s[A228303] but was granted FDA approval in 1952.[A228308]

    Products: VELGASTIN BLAEHUNGEN SUS
  3. Drug

    Glyburide

    go.drugbank.com/drugs/DB01016
    ApprovedInvestigational

    Glyburide is a second generation sulfonylurea used to treat patients with diabetes mellitus type II. It is typically given to patients who cannot be managed with the standard first line therapy, metformin. Glyburide stimulates insulin se...

  4. Drug

    Tivozanib

    go.drugbank.com/drugs/DB11800
    ApprovedInvestigational

    [L32529] Tivozanib, also known as FOTIVDA, is a kinase inhibitor developed to treat adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) after prior failed systemic therapies

  5. Drug

    Aflibercept

    go.drugbank.com/drugs/DB08885
    ApprovedInvestigational

    [A261130,L47915] Ziv-aflibercept, under the brand name Zaltrap, was developed as an intravenous injection for the treatment of metastatic colorectal cancer, and it was approved by the FDA and EMA in … biosimilars—Yesafili (aflibercept-jbvf)[L53043] and Opuviz (aflibercept-yszy)[L53038], approved in May 2024, and Ahzantive (aflibercept-mrbb)[L53048], approved in July 2024—were authorized by the FDA as

  6. Drug

    Loxapine

    go.drugbank.com/drugs/DB00408
    ApprovedInvestigational

    An antipsychotic agent used in schizophrenia. [PubChem]

  7. Drug

    Encorafenib

    go.drugbank.com/drugs/DB11718
    ApprovedInvestigational

    Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. … Mutations in this gene, most frequently the V600E mutation, are the most commonly identified cancer-causing mutations in melanoma, and have been isolated in various other cancers as well, including non-Hodgkin

  8. Drug

    Mitomycin

    go.drugbank.com/drugs/DB00305
    ApprovedInvestigational

    well as adjunctly to _ab externo_ glaucoma surgeries. … has resulted in its approval for the treatment of a variety of cancers - the most recent of which is an April 2020 approval for its use in low-grade Upper Tract Urothelial Cancer (LG-UTUC)[L12867] - as

  9. Drug

    Indapamide

    go.drugbank.com/drugs/DB00808
    ApprovedInvestigational

    [A204155] Thiazide-like diuretics such as indapamide are a valuable tool for the treatment of hypertension and continue to grow in popularity, falling behind only ACE inhibitors in terms of prescription

  10. Drug

    Trandolapril

    go.drugbank.com/drugs/DB00519
    ApprovedInvestigational

    Trandolapril may be used to treat mild to moderate hypertension, to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction, as an adjunct treatment